“…Previous studies have shown that HER2 gene amplification was present in 10-20% of NSCLC patients (6,7). Notably, HER2 amplification rates have been shown to be associated with the drug resistance in NSCLC (8,9). At present, the clinical detection of HER2 amplification is generally by immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) (10).…”